New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:16 EDTLXK, ITW, PLXT, ALSN, RVNC, BEBE, FB, XRX, MCD, HOG, GSK, NVS, FEYE, CMCSA, NFLX, VRX, AGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Netflix (NFLX), up 8%... Harley-Davidson (HOG), up 7%... PLX Technology (PLXT), up 8%... Illinois Tool (ITW), up 2.3%... Comcast (CMCSA), up 1%... McDonald's (MCD), up 0.6%. ALSO HIGHER: Allergan (AGN), up 17% after Valeant (VRX) confirms proposal to combine with the company for $48.30 and 0.83 shares of stock. Valeant is up 5% following its confirmation of the news that broke last night... GlaxoSmithKline (GSK), up 4.5% after agreeing to sell oncology products for $14.5B to Novartis (NVS) and buy Novartis' Vaccines business, currently excluding its flu business, for $7.1B plus royalties. Novartis shares trading in New York are also up 1% following the deals... Revance Therapeutics (RVNC), up 20% after announcing positive results from RT002 Phase 1/2 study... Facebook (FB), up 2% following upgrade at Credit Suisse. DOWN AFTER EARNINGS: Xerox (XRX), down 4%... Lexmark (LXK), down 4.8%. ALSO LOWER: Allison Transmission (ALSN), down 4% after filing to sell 25M shares for holders... FireEye (FEYE), down 2.9% after filing to sell 13.3M shares of common stock for holders... Bebe stores (BEBE), down 16% after reporting preliminary Q3 losses that were steeper than the consensus estimate.
News For AGN;VRX;NFLX;CMCSA;FEYE;NVS;GSK;HOG;MCD;XRX;FB;BEBE;RVNC;ALSN;PLXT;ITW;LXK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
October 13, 2014
08:50 EDTNFLXNetflix charging extra for 4K Ultra HD content, Variety reports
Netflix will require subscribers to pay its most expensive service tier for 4K Ultra HD content, reports Variety. Subscribers must sign up for the "family" plan at $11.99 monthly, which allows for simultaneous streaming of up to four programs. The reason for the change was that producing and acquiring 4K content costs more that conventional HD, so it has repositioned Ultra HD as a premium offering. Reference Link
07:43 EDTNFLXNetflix Q3 results expected to be inline, says Canaccord
Subscribe for More Information
07:12 EDTGSKOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
06:32 EDTCMCSAUniversal receives approval to open $3.27B theme park in Beijing, WSJ reports
Subscribe for More Information
05:15 EDTFBFacebook, Ericsson, XL Axiata innovate to improve Indonesia network performance
Subscribe for More Information
October 12, 2014
17:34 EDTFEYEJPMorgan to double spending on cybersecurity over next five years, WSJ says
Subscribe for More Information
15:54 EDTCMCSA21st Century Fox's 'Gone Girl' wins at box office with $26.8M, Bloomberg says
21st Century Fox's (FOX, FOXA) “Gone Girl” took first place at the box office this weekend taking in $26.8M, says Bloomberg. "Dracula Untold,” from Comcast's (CMCSA) Universal Pictures came in second this weekend taking in $23.5M, added Bloomberg. Reference Link
October 10, 2014
17:14 EDTAGNMarket ends week lower amid global growth worries
Subscribe for More Information
16:02 EDTFB, NFLXActionable Options for Friday, October, 10
Subscribe for More Information
13:17 EDTCMCSANielsen to restate some TV rating due to software glitch, Variety reports
Nielsen (NLSN) acknowledged it uncovered a software error on October 6 that had resulted in TV ratings being allocated incorrectly among broadcast and syndication programming since March 2 and that it would restate the ratings accordingly to fix the errors, reported Variety. The company said 98% to 99% of ratings would not be affected by more than .05 of a ratings point and a person familiar with the situation said some TV networks have an expectation that some of their new fall programming will see a very slight uplift due to the restatement, the report noted. The big four broadcast networks are operated by CBS (CBS), Comcast (CMCSA), Disney (DIS) and 21st Century Fox (FOXA). Reference Link
10:20 EDTAGNFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
10:07 EDTFBFacebook, peer-to-peer lending groups in discussions, The Information says
Subscribe for More Information
07:57 EDTFBFacebook, India Telecom Minister discuss expanding in India, Economic Times says
Facebook CEO Mark Zuckerberg and India's Telecom Minister Ravi Shankar Prasad met to discuss expanding the reach of internet by using alternate technology, reports The Economic Times. According to sources, Facebook requested Prasad establish single point contact in his ministry for the alternative technology to which the minister immediately agreed. Reference Link
07:37 EDTVRX, AGNActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:35 EDTAGNAllergan price target raised to $224-$225, from $198-$199 at Wells Fargo
Wells Fargo increased its price target on Allergan after the company pre-released better-than-expected revenue and EPS, and raised its 2014-2016 EPS guidance. The firm keeps an Outperform rating on the shares.
07:16 EDTVRX, AGNAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
07:04 EDTCMCSAAmazon in talks to join digital locker for movies. WSJ reports
Subscribe for More Information
06:39 EDTNFLXNetflix spends $150M annually on content recommendations, Gigaom reports
Subscribe for More Information
05:13 EDTNVSNovartis reports new analyses of AIN457 Phase III data show consistent efficacy
Novartis announced that new analyses of AIN457 Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity. Secukinumab's new mode of action stops interleukin-17A, which plays a central role in the development of psoriasis. In the analyses, the majority of patients across two disease severity subgroups, including those with severe psoriasis, experienced complete clear to almost clear skin measured as 100 or 90% reduction of respective baseline PASI, or Psoriasis Area and Severity Index. Skin clearance was sustained through one year of treatment. This is important as historically, psoriasis patients' disease severity at the start of treatment has been shown to negatively impact their response to other therapies. Disease severity subgroups were PASI less than or equal to 20 and PASI greater than 20. PASI measures redness, scaling and thickness of psoriatic plaques and the impact in regions of the body. These findings reconfirm the significantly better responses seen in the published FIXTURE study, where secukinumab showed superiority to Enbrel, a standard of care anti-TNF medication.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use